MX2009010193A - Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos. - Google Patents

Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos.

Info

Publication number
MX2009010193A
MX2009010193A MX2009010193A MX2009010193A MX2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A
Authority
MX
Mexico
Prior art keywords
nos
related compounds
tetrahydroquinoline
quinolone
inhibitory activity
Prior art date
Application number
MX2009010193A
Other languages
English (en)
Spanish (es)
Inventor
Shawn Maddaford
Jailall Ramnauth
Suman Rakhit
Joanne Patman
Paul Renton
Subhash C Annedi
Peter Dove
John Andrews
Sarah Silverman
Original Assignee
Neuraxon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxon Inc filed Critical Neuraxon Inc
Publication of MX2009010193A publication Critical patent/MX2009010193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009010193A 2007-03-23 2008-03-25 Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos. MX2009010193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89682907P 2007-03-23 2007-03-23
PCT/CA2008/000569 WO2008116308A1 (en) 2007-03-23 2008-03-25 Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity

Publications (1)

Publication Number Publication Date
MX2009010193A true MX2009010193A (es) 2009-12-15

Family

ID=39775375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010193A MX2009010193A (es) 2007-03-23 2008-03-25 Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos.

Country Status (14)

Country Link
US (1) US8173813B2 (enExample)
EP (1) EP2139886A4 (enExample)
JP (1) JP2010521527A (enExample)
CN (1) CN101679397A (enExample)
AR (1) AR065845A1 (enExample)
AU (1) AU2008232269A1 (enExample)
CA (1) CA2681771A1 (enExample)
CL (1) CL2008000838A1 (enExample)
IL (1) IL201142A (enExample)
MX (1) MX2009010193A (enExample)
NZ (1) NZ580618A (enExample)
TW (1) TWI417099B (enExample)
WO (1) WO2008116308A1 (enExample)
ZA (1) ZA200907458B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CA2705835A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
AU2009296803A1 (en) * 2008-09-29 2010-04-01 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
FR2984318B1 (fr) 2011-12-16 2014-06-27 Oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations
FR2984323B1 (fr) * 2011-12-16 2019-08-30 L'oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines, composition tinctoriale en comprenant, procedes et utilisations
AU2013369649B2 (en) * 2012-12-31 2018-07-26 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
EP2986587B1 (en) 2013-04-17 2023-11-22 Sharon Anavi-Goffer Cb2 receptor ligands for the treatment of psychiatric disorders
KR20160023686A (ko) * 2013-06-26 2016-03-03 다이이찌 산쿄 가부시키가이샤 3 고리성 복소 고리 화합물의 제조 방법
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN109206385B (zh) * 2017-07-03 2022-04-22 扬子江药业集团有限公司 一种地佐辛杂质a及其同系物的制备方法
FR3072286B1 (fr) 2017-10-13 2022-08-12 Oreal 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition
CN108853509A (zh) * 2018-05-03 2018-11-23 浙江大学 抑郁症的治疗和药物组合物
CN109053712A (zh) * 2018-09-19 2018-12-21 南京大学连云港高新技术研究院 一种2-氨基噻吩-3-羧酸甲酯衍生物c15h22n2o5s的合成方法
KR20210127137A (ko) 2018-12-05 2021-10-21 노쓰웨스턴유니버시티 면역요법을 위한 뉴런 옥시드 신타제 억제제
WO2021127391A1 (en) * 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022056736A1 (zh) * 2020-09-16 2022-03-24 中国科学院深圳先进技术研究院 左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用
CN115073370B (zh) * 2021-03-10 2024-12-17 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
US20250221959A1 (en) * 2022-03-17 2025-07-10 Vasoceuticals, Inc. Combined use of individual compounds for treatment of chronic pain disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087561A (en) 1975-12-22 1978-05-02 Canada Packers Limited Control of nitrosamine formation in nitride cured meat with 1,2,3,4-tetrahydro-quinoline compounds
FR2358151A1 (fr) 1976-03-31 1978-02-10 Roussel Uclaf Nouvelles benzazepines et leurs sels, procede de preparation et application a titre de medicaments
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
AU548467B2 (en) 1980-08-12 1985-12-12 Glaxo Group Limited Tryptamines and their isoindolylethyl derivatives
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4710507A (en) 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
US4963677A (en) * 1987-12-30 1990-10-16 Orion Corporation Ltd. Heterocyclic lactam compounds
EP0322746B1 (en) * 1987-12-30 1996-05-29 Orion Corporation Limited Heterocyclic compounds
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
ATE177078T1 (de) * 1993-10-21 1999-03-15 Searle & Co Amidino-derivate als no-synthetase inhibitoren
ZA95878B (en) * 1994-02-03 1996-01-16 Cambridge Neuroscience Inc Therapeutic guanidines
MX9605366A (es) * 1994-05-07 1997-12-31 Astra Ab Derivados de amidina biciclicos como inhibidores de la oxido nitrico sintetasa.
AU730369B2 (en) * 1996-11-25 2001-03-08 Board Of Regents Of The University Of Nebraska, The Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
ID22812A (id) 1996-11-25 1999-12-09 Procter & Gamble Senyawa 2-imidazolinilaminoindol yang berguna sebagai agonis adrenoseptor alfa-2
JPH10265450A (ja) * 1997-03-25 1998-10-06 Mitsui Chem Inc 一酸化窒素合成酵素阻害作用を有する新規なアミジン誘導体
US6166030A (en) * 1997-05-05 2000-12-26 Astra Aktiebolag Compounds
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
JP2004536079A (ja) * 2001-05-16 2004-12-02 アンテックスファーマ・インコーポレーテッド 置換１−ベンズアゼピンおよびその誘導体
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
CA2370751A1 (en) * 2002-02-05 2003-08-05 Garth B.D. Shoemaker Fast and accurate rendering of pliable display technology distortions using pre-calculated texel coverages
BR0308429A (pt) * 2002-03-14 2005-01-11 Bayer Healthcare Ag Aroilpiridinonas monocìclicas como agentes antiinflamatórios
US20050171195A1 (en) * 2003-11-06 2005-08-04 Carroll William A. P2X7 antagonists for treating neuropathic pain
CN101247853B (zh) 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
JP2009501184A (ja) 2005-07-13 2009-01-15 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６、５−ｈｔ２４としてのベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
TW200902003A (en) 2009-01-16
WO2008116308A1 (en) 2008-10-02
NZ580618A (en) 2012-07-27
IL201142A (en) 2013-12-31
TWI417099B (zh) 2013-12-01
AR065845A1 (es) 2009-07-08
EP2139886A1 (en) 2010-01-06
JP2010521527A (ja) 2010-06-24
IL201142A0 (en) 2010-05-17
CL2008000838A1 (es) 2008-10-10
CA2681771A1 (en) 2008-10-02
CN101679397A (zh) 2010-03-24
AU2008232269A1 (en) 2008-10-02
US20080234237A1 (en) 2008-09-25
EP2139886A4 (en) 2011-03-30
ZA200907458B (en) 2011-01-26
US8173813B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
MX2009010193A (es) Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos.
MX2010005343A (es) Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
TR201909189T4 (tr) C-kit ki̇naz i̇nhi̇bi̇törü bi̇leşi̇kler ve bi̇leşi̇mler
EP4116293A3 (en) Rho kinase inhibitors
PH12013502099A1 (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
WO2010124283A3 (en) Methods and compositions relating to hematologic malignancies
WO2008057691A3 (en) Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
IL200315A (en) Glutaminyl Cyclase Inhibitors for Diagnosis and Treatment of Light Cognitive Defect, Vascular Shortening and Pancreatitis
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
EP3341034A4 (en) ANTIMICROBIAL AND ENZYME-INHIBITING ZINC OXIDE NANOPARTICLES
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
EP4385576A3 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2010081662A3 (en) Methods for identifying patients who will respond well to cancer treatment
TW200638937A (en) Use of EGFR tyrosinekinase inhibitors for treatment of chronic rhinosinusitis
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2015100423A3 (en) Methods for treating cancer with ghrh agonists

Legal Events

Date Code Title Description
FG Grant or registration